Netarsudil: a novel intra-ocular pressure lowering agent
Loading...
Date
2018-11
Journal Title
Journal ISSN
Volume Title
Publisher
Medip Academy
Abstract
Optic disc health is an important indicator of visual functions. The first line of management to prevent/halt the damage to optic disc is to control responsible pathological condition, if identified. In absence of identifiable cause, the most validated approach is lowering of intra-ocular pressure (IOP). Individually, as well as combinations of currently available drugs are not fully effective in all patients of glaucoma in achieving desired IOP control. Hence, there is a need of newer alternatives which address this unmet need. Recently, a newer IOP lowering agent with a novel mechanism of action, netarsudil, has been approved by United States Food and Drug Administration (US-FDA) in December 2017. Netarsudil acts by inhibiting Rho-associated protein kinase resulting in lowering of overall tone of the contractible cells in trabecular meshwork thereby improving drainage of aqueous humor outflow and lowering of IOP. Though in its early days, this drug gives an armamentarium to ophthalmologists and physicians to control IOP in patients of open-angle glaucoma and ocular hypertension.
Description
Keywords
Intra-ocular pressure, Netarsudil, Rho kinase inhibitor
Citation
Ghanghas Ravi R., Mohan Prafull, Sharma Vikrant, Sharma Ashok K.. Netarsudil: a novel intra-ocular pressure lowering agent. International Journal of Basic & Clinical Pharmacology. 2018 Nov; 7(11): 2268-2270